<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 55 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page54.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=55">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 55 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 55</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=55"><img src="../thumb/55.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>24 / 2020-04                                                        Central Nervous System - 1.5.3
   reduct.if hypotens.develops, re-eval. dos.on discont.of carbamazep./   mg/day. Adjust dos.accord.to clinic.respon. & tolerabil.with range of   drug react.with eosinoph.& system.sympts., acne, psorias., alopec.,
   hepat. enzym.induc., re-eval.ther if concom.fluoxetine init./discont  200-800 mg/day. Usual effect.dos.: 400-800 mg/day.  face swell., musc.-skelet. rigidity/discomf., musc.cramp, extremity
   Interactions: Use with other concom.meds.not system. eval., CNS   Elderly: Init.25 mg/day, theraft.incr.dly.dos.in increm.of 25-50 mg.to   pain, joint stiffn., trismus, enures., urin.incontin., dysur., erect.dys-
   depress.with alcoh.& other centr. act.meds., may antagon.eff.of   an effect.dos.poss.low.than young.pts.  funct., erection incr., priapism., galactorrh., gynaecomast., asthen.,
   levodopa & other dopamine agonists, carbamazepine & other hepat.   Contraindications: Safety in pregn.& lactat.not est., safety in ad-  headache, fatig., chest discomf., gait abnorm., thirst, pain, feel.hot,
   enzyme induc.may decr.plasma lev., incr. plasma lev.with fluoxetine/  vanc.liv.& ren.impairm.not est., safety & effic.in childr.& adolesc.  pyrex., hepat.enzyme incr., bld.lact. dehydrogen. incr., eosinophil., loc.
   paroxet./venlafaxine./ phenothiaz./TCA’s/& some ß-block., C max of   bel.18 yrs.not est., co-admin.of cytochrome P450 3A4 inhibit.eg.   reacts.for inj.,laryngismus, sweat., allerg.reacts., man., hypoman., flu
   valproate incr., Li-Tmax incr., cimetidine & ranitidine incr.bioavailabil.  (HIV prot.inhibit./azole antifung.agents/ erythromyc. & clarithromyc.)  syndr., angioed., facial weakn., serotonin syndr
   CLOMENT, Litha [P/S]         Side effects: Somnol., dizzin., dry mouth, asthen., constipat., tachy-  Warnings and special precautions: Teratogen. in anim., low
                                                              ser.K&/Mg to be replet. bef.init.treatm., monit electrol wth diuret.
                                card., orthostat.hypotens., dyspeps., weight gain., syncope, neuro-
   Clozapine.                   lept. malign. syndr., leucopen., neutropen., periph.oed., bld. dyscras.,   ther., risk of further QTc prolongat.& dysrhythm.incr.with persist.pro-
   Indications: Ther.resist.schizophren.  hypersens.incl.anaphylax., hyperglycaem. sometim. extreme assoc.  long QTc interv.& not clear if rout.ECG screen.effect.detect., avoid in
   (S5) TABS. 35/2.6.5/0373, 0374  with ketoacidos./coma/ death, diab.mellit./pre-exist.diab.exacerbat.,   signif.CV illn.hist., discont.if QTc measurem. persist.&gt;500 msec., eval.
   700176-001: 25 mg, 100, R367,00  hyperprolactinaem., hypothyroid., inappropr.ADH secret., CNS effs.,   sympts.indicat.of torsades de pointes, discont.if neurolept.malign.
   700178-001: 100 mg, 100, R1 113,00  headache, syncope, anx., extrapyramid. sympt., dysarth., seiz., tard.   syndr. devel., with S&S of tard.dyskines.consid. discont./ dos. reduct.,
   Dosage: Indiv.using lowest effect.dos. Init: 12,5 mg once/twice on   dyskines., restless legs syndr., dry eyes, asymptomat. chang.in eye   seiz.hist., clos.monit.of high risk suic.pts., concom.CNS drugs & drugs
   1st day, follow.by 25-50 mg on 2nd day, if well tol.may be incr.slow.  lens.with longt.use, blurr. vis., ear/chest/back pain, card./menstr. /  act. on dopaminerg.& serotonerg.syst., caps. cont.lact., breast feed.
   in increm. of 25-50 mg up to 300 mg/day within 2-3 weeks. There-  psych. disords., QTc interv. prolongat., ven. thromboembol., dyspn.,   not advis., given CNS effs. concom. central act.agents incl.alcoh.&
   aft. if reqd.dly.dos.may be further incr.in increm. of 50-100 mg at half/  rhinit., pancreatit., GI disturbs. incl.intest. obstruct./ileus, jaund.,   meds. act. on dopaminerg.& serotonerg.systs., approp. meth.of con-
   pref. wkly interv. Therapeut. dose range expect.at 200 -450 mg/day in
   div.dos. Some pts.may require up to 600 mg/ day. Max.dos.900 mg/  hepatit., skin reacts.incl.Stev.John.syndr./tox. epiderm.necrolys./  tracept.in women of child-bearing potent, elderly, imp.ren.funct.for
                                                              inj., low.dos.in mild to mod.hepat.impairm., exper.lack.in sev. hepat.
                                erythema multiforme, angioed., myalg., rhabdomyolys., UTI, urin.re-
   day Maint: Once max. therapeut. benef.achiev., careful downward
   titrat. recomm. & to be maint.for at least 6 mnths. If dly dos. does   tent., priapism, galactorrh., sex.dysfunct., breast swell., periph. oed.,   insuffic., discont.if sev.cutan.adv.reacts occur, not approv.for elderly
                                                              dement.relat. psychos.
                                ac withdr.sympt., fev., hypotherm., elev.ser. transamin./cholester./tri-
   not exceed 200 mg sngl.even.dly dos. poss. Grad.reduct.over 1-2 wk.
   period recom.if to be terminat. Re-initiat: If interv.since last dos. ex-  glycerid., decr.in thyroid horm. lev., akathis., accident.inj.esp.elderly,   Drug interactions: Effs.of dir.& indir.dopamine agonists poss an-
                                agranulocytos., dysphag.
                                                              tagon., ketoconaz.potent CYP3A4 inhibit.incr.AUC & C max.expos. car-
   ceeds 2 days commenc.with 12,5 mg once/twice on 1st day, if well
   tol.it may be poss.to titrate to therapeut. dos more quickly than init.  Warnings and special precautions: Poss. worsen. of depress.&   bamazepine decr.ziprasidone expos.
                                                              See also MDR page 618-621.
   treatm., however if prev.resp./card.arrest exper.re-titrat. with extreme   emerg.of suic.ideat./self-harm in bipol.disord., monit.pts. esp.dur.
   caut. Only switch to Cloment from classic. neurolept.aft.grad.reduct.  early ther. & dos. chang.for clinic.worsen.& suicidal., risk persist. unt.  INVEGA, Janssen Pharmaceutica [P/S]
   over appox.1 wk. Treatm. may be introduc.as above.when other neu-  signif.remiss.occurs, observ.same precaut. as those for other psychi-  Paliperidone
   rolept. has been discont.for at least 24 hrs.  atr./non-psychiatr. disords., caref.monit.of pts.at great.risk eg. those   Indications: Schizophren.in adults & adolesc. 12-17 yrs.of age. Not
   Contraindications: Granulocytopen./ agranulocytos./ neutropen.  with suic.relat.events hist./ exhib.suic. ideat. prior to ther.init., taper   stud.in pts. unrespons.to risperidone. Schizoaffect.disord.in adults
   hist., concom.agents with bone marrow funct.suppress.potent., imp.   dos.with discont., monit.gluc.contr.of exist.diabet./ hyperglycaem.   as monother. & in combinat.with antidepress./mood stabilis.meds.
   bone marr.funct./ myeloproliferative disords./white bld. cell abnorm./   sympt.in those at risk, fast.bld.gluc.test.advis.for those develop.hy-  (S5) PR TABS, 42/2.6.5/0284, 0285, 0286
   different.bld.count, uncontroll. epilep., alcoh./tox.psychos., drug in-  perglycaem. sympt.dur.ther., cont. anti-diab.meds.poss.necess.de-  715666-001: 3 mg, 28, R1 902,03
   toxic., comat. condits., glauc., circulat.collapse &/CNS depress. of   spite ther.discont., metabol.paramet.to be assess. bef.init.treatm.&   715667-001: 6 mg, 28, R1 902,03
   any cause, sev.ren./card.disords., act./progress. liv. dis., hepat.fail.,   chang. contr., incr.extrapyramid.sympt.incid., cons. discont. if tard.  715668-001: 9 mg, 28, R2 252,46
   safety in childr.und.16 yrs.not est., pregn.& lactat., concom.long-act.  dyskines.S&S occur, known CV dis./ other condits.predispos.to hypo-  Dosage: Do not alt.betw.admin.in fasting/fed state. Do not chew/
   depot antipsycot.            tens., seiz.hist., discont. if sympt.of neurolept.malign.syndr.occur, sev.   div./crush tab.
   Side effects: Seiz., fatal agranulocytos., granulocytopen., eosino-  neutropen.somet.fatal in risk pts., discont. ther. if neutroph.count &lt; 1,0   Schizophrenia: Adults: Recomm.dos: 6 mg once dly.in the morn.
                                  9
   phil.&/leucocytos., orthostat. hypotens., circulat.collapse accompan.   x 10 /lit., fev./infect. sympt. to be report.esp.without predispos.fact.,   standardis.in relat.to food. Dos. range: 3-12 mg once dly. Adjust dos.
   by resp.depress./arrest, sedat., weight gain, drowsin., fatig., dizzin.,   monit. weight gain/lipid chang./elderly/pts.with intest. obstruct./il-  only aft.clinic .reassessm. & in increm.of 3 mg/day at interv.&gt;5 days.
   headache, EEG chang., confus., restlessn., agitat., delir., extrapyramid.   eus, QT prolong.family hist., concom. meds.known to incr.QT interv./  Adolesc.(12-17 yrs.): Recomm.dos: 3 mg once dly.in the morn.
   sympt., rigidity, trem., akathis., poss.tard.dyskines., neurolept. malign.  concom. neurolept. esp.in pts.with incr.QT prolong.risk, cardiomyo-  standardis.in relat.to food. Dos.range: 3-12 mg once dly. Adjust dos.
   syndr., dry mouth, blurr.vis., sweat/ temp.regul.disturb., hypersalivat.,   pathy/ myocardit., poss.dos.adjustm. with phenytoin/other concom.  only aft. clinic.reassessm. & in increm.of 3 mg/day at interv. &gt;5 days.
   tachycard., hypertens., ECG chang., card.arrhythm., pericardit., myo-  hepat.enzyme induc., not for use in elderly with dement. exhibit.behav.   Schizoaffect.disord: Adults: Recomm.dos: 6 mg once dly.in the
   cardit., ven./pulm.thromboembol., dysphag., GI disturbs., hepatit.,   disturbs., low.effect.dos.in elderly when consid. essent., pts.at risk   morn. standardis.in relat.to food. Dos.range: 3-12 mg once dly.
   cholest.jaund., hepat. necros., ac.pancreatit., urin.incont./retent.,   for aspirat.pneum., concom. grapefruit juice not recomm., VTE risk   Adjust dos.only aft. clinic.reassessm. & in increm.of 3 mg/day at
   priapism, ac.interstit. nephrit., benign hypertherm., skin reacts., hy-  fact. identif. bef.& dur.ther., lact.intol., ren./hepat.impairm., concom.  interv.&gt;4 days.
   perglycaem., sudd.unexpl.death.  antihypertens.or caus.electrol.imbal.  Contraindications: Risperidone hypersens., sev.ren.impairm., decr.
   Special precautions: Reduc.dos.if seiz.occur, agranulocytos./ seiz.  Interactions: Other CNS act.drugs & alcoh. poss. aggrav.prim.  GI transit time, dement., Parkinsons dis., safety in pregn.not est.,
   risk, advise pt.against potent. hazard. activ.dur.ther., concom.meds./  CNS effs., act.of dopaminerg. antagonis., incr. clear.with concom.   breast feed., safety & effic.in treatm.of schizophren.in pts.und.12 yrs./
   alcoh., if pregn. occurs,dos.instructs.if ther.discont.for more than 2   thioridazine/ carbamazepine/ phenytoin/ other hepat.enzyme in-  schizoaffect.disord.in pts.und.18 yrs. not est., lact intol.3 mg tab.only,
   days, avoid extend.treatm.if respons. inadeq., re-eval.period., throm-  duc., signif.incr.in quetiapine AUC with ketoconazole, ser.conc.poss.  Side effects: Neurolept.malign.syndr.incl rhabdomyolys & ac.ren.
   boembol.risk, elderly, underweight pts.& ren./hepat./CV disords. (low   aincr.with grapefr. juice.  fail., tard.dyskines., hyperglycaem., orthostat.hypotens., obstruct.
   init.dose, slow incr.), discont.in case of NMS/ myocardit./ if jaund.  GEODON, Pfizer [P/S] &  sympts. with known strictures in assoc.with ingest. of meds.with
   devel., prostat.enlargem., narr. angle glauc., outweigh benef.-risk in   Ziprasidone  non-absorb.shell, QT prolongat., ventric.arrhythm., sudd.unexplain.
   prim.bone marrow disord.hist., benign ethnic neutropen., do not re-  Indications: Ac.exacerbat.& maint.of clinic. improvem. dur.con-  death, card.arrest, torsade de pointes, headache, tachycard., aka-
   expos.pts.if discont.as a result of WBC defic., concom.meds.with   tinuat.ther.in schizophren.  thisia, extrapyramid.disord., somnol., dizzin., sedat., trem., hyperton.,
   anticholinerg./ hypotens./resp.depress.effs.  (S5) CAPS, 32/2.6.5/0584, 0585, 0586, 0587  dyston., dry mouth, weight incr., saliv.hypersecret., vomit., dyskines.,
   Warnings: Limit use to sev.ill pts.non-respons./ intol. to class.neuro-  703465-001: 20 mg, 60, R1 1239,52  Parkinson., anaphylact.react., metabol.& nutrit.disord., psych.disords.,
   lept.drug treatm., monit.evid.of infects./ flu-like sympt./fev., pts.must   703468-001: 40 mg, 60, R1 299,00  convuls., syncope, oculogyrat., AV block, bradycard., bundle branch
   have norm. WBC count bef.init.ther., wkly.WBC count & ANC monit.   703475-001: 60 mg, 60, R1 744,32  block, sinus tachycard./-arrhythm., palpitat., ischaem., abdom.pain,
       st
   prior/dur.1  18 wks.thereaft.2 wkly & x 4 wks. aft.treatm., close medic.  703476-001: 80 mg, 60, R2 133,86  musc.rigidity, amenorrh., breast discharge, erect.dysfunct., galact-
   supervis.when init. ther. as collapse poss.accompan.by card.and/or   Dosage: Admin.with food.  orrh., gynaecomast., menstr.irregul., asthen., fatig., oed., abnorm.ECG.
   resp. arrest more like to occur dur.init.titrat.in assoc. with rapid dos.  Adults: Recomm.init.dos: 40 mg 2xdly. Adjust accord. to clinic.  As act.metabol.of risperidone addit.AE’s report. with risperidone:
   escalat., hist.of seiz./other predispos. fact.as dos.appears to be an   respons.up to max.80 mg 2xdly. Max.dly.dos. may be reach.as   pneumon., flu, bronchit. URTI. UTI, rhinit., vir.infects., cellulit., eye in-
   imp. predictor of seiz.incr. with high.dos.theref. activ. where sudd.  early as day 3.  fects., loc. infects., acaropdermatit., onchomycos., bld. dyscras., hy-
   loss of consciousn.could cause ser. risks not advis.  (S5) IM INJ, 36/2.6.5/0478, 36/34/0479  persens.reacts., hyperprolactaem., inappropr.antidiuret.horm.secret.,
   Drug interactions: Poss.interact.with anticonvuls. meds., enhanc.  Indications: Ac.agitat.in schizophren.where rapid control reqd.  decr.appetite, anorex., polydips., diabet.ketoacidos., water intoxicat.,
   CNS eff.of alcoh./ MAOI’s/CNS depress., incr.neurolept.malign. syndr.   703467-001: 20 mg/ml, 1 vial+dil., R177,05  insomn., anx., sleep disord., confus., mania. decr.libido, restlessn.,
   developm.risk with Li., incr.risk of circulat. collapse & resp.depress.  Dosage: IM inj.when oral formulat.inappropr. Reconstit.only with   agitat., anorgasm., blunt.affect, CVA, unrespons.to stimuli, depress./
   with benzodiazepin./any other psychotrop., other highly prot.bound
   meds. may incr.plasma conc./displace it., cimetid./ erythromycin may   water for inj. If long term ther. necess.switch to oral formulat. ASAP.   loss of conscousn., TIA’s, attent.disturbs., hypersomn., bal.disord.,
                                                              speech disord., abnorm. co-ordinat., hypoaesthes., drool., blurr.vis.,
                                Admin.for &gt;3 consec.days not stud.
   incr.plasma lev., poss.incr. plasma lev.with meds.that are known to   Adults: Recomm.dos: 10-20 mg as reqd.to max. 40 mg /day. 10 mg   ocul. hyperaem., incr.lacrimat., photophob., eyelid oed., glauc., ear
   bind with P450 2D6, incr.plasma lev.of TCA’s/phenothiazin./ type 1 C,   dos.maybe rep.every 2 hrs. Init. dos.of 20 mg may be reqd.which   pain, tinnit., flush., dyspn., epistax., cough, nas.congest./oed., phar-
   anti-arrhythm., incr.with fluvoxamine/other SSRI’s, phenytoin & other   maybe follow.by furth.10 mg dos.aft.4 hrs.thereaft. 10 mg dos.every   yngolaryngeal pain, wheez., rales, product.cough, sleep apnoea,
   meds.known to induc. P450 enzyme may reduc.plasma lev., BP incr.  2 hrs.to max.40 mg/day.  hyperventilat., GI disturbs., jaund., erythema, angioed., prurit., acne,
   eff.of adren. & derivat.poss.revers.  Contraindications: Inj.in elderly (&gt;65 yrs), do not mix.with other   skin discol., alopec., seborrhoeic dermatit., dry skin, rash, dandruff,
   DOPAQUEL, Dr Reddy’s [P/S]   meds/solv., known QT interv. prolongat., congenit./acquir.long QT   arthralg., back pain, extremity pain, musc.weakn./-spasms/-twitch.,
   Quetiapine fumarate          syndr., meds. known/observ.to prolong.QT interv., rec.MI, uncom-  myalg., neck pain, joint swell./-stiffn., abnorm.posture, musculoskelet.
   Indications: Schizophren., manic episod.assoc.bi-polar disord.for   pens.HF, card.dysrhythm.treat. with Class I A & III anti-dysrhythm.  stiffn./-chest pain, torticollis, enures., dysur., urin. incontin., pollakiur.,
   which safety & effic.beyond 12 wks.not demonstrat.  drugs, pregn.& lactat., safety & effic.in childr.und.18 yrs.not eval.,   sex.dysfunct., ejaculat. disord., priapism, vag.discharge, pyrex., pe-
   (S5) TABS. 43/2.6.5/0429, 0430, 0431, 0432  safety & effic in CV dis.not est.  riph.-/fac.oed., hypotherm., drug withdr.syndr., periph. coldn., thirst,
   716050-001: 25 mg, 100, R254,00  Side effects: Mild to mod.prolongat.of QT interv. & torsades de   sluggishn., dysgeus.
   716051-001: 100 mg, 90, R432,53  pointes, neurolept.malign. syndr., tard.dyskines.with long.term.ther.,   Warnings and special precautions: Known CV dis., QT prolon-
   716052-001: 200 mg, 60, R465,58  sedat., akathisia, extrapyramid.disord., dizzin., rhinit., incr. appetite,   gat. fam.hist.& other meds.thought to prolong QT interv., discont.if
   716053-001: 300 mg, 60, R544,20  hypocalcaem., psych.disords., CNS effs., dyston., Parkinsonism,   neurolept.malign. syndr./S&S of tard.dyskines.develop, risk vs. ben-
   Dosage: Adults: Admin.twice dly.  gen.ton.clon.seiz., tard. dyskines., dyskines., drooling, atax., dys-  ef. in Parkinsons or dement.with Lewy Bodies as NMS & antipsych.
   Schizophren: Tot.dly.dos.for 1  4 days: Day 1: 50 mg, day 2: 100 mg,   arthr., oculogyric cris., attent.disturb., hypersomn., hypoaesthes.,   sensitiv.risk incr., monit.gluc. control of exist.diabet./hyperglycaem.
                st
   day 3: 200 mg & day 4: 300 mg. Titr.dos.from 4  day to effect.dos.  paraesthes., lethargy, torticoll., paresis., akines., hyperton., restless   sympts.in those at risk, condits.predispos.to hypotens., seiz hist./
                       th
   range of 300-450 mg/day. Adj.dos.in some pts.within 150-750 mg/  leg syndr., lymphopen., palpitat., tachycard., bradycard, blurr. vis.,   condits.low.seiz.threshold, patholog./ iatrogen. GI narrow., dysphag.,
   day range depend.on clinic.response & tolerab.  photophob., amblyop., vis.disturbs., eye prurit., dry eyes, vertigo,   diffic.in swallow. tabs., condits.lead.to short GI trans.time, ren./ sev.
   Manic episod.assoc.bipol.disord: Tot.dly.dos. for 1  4 days: Day   tinnit., ear pain, vasodilat., hypertens. cris,hypertens., orthostat.  hepat.impairm., not stud.in elderly with dement. although incr.risk
                         st
   1: 100 mg, day 2: 200 mg, day 3: 300 mg & day 4: 400 mg. Furth.dos.  hypotens., hypotens., postur.hypotens., dyspn., sore throat, hiccups,   of mortality & incr.incid.of cerebrovasc. advers.events report.in such
   adjustm upto 800 mg/day by day 6 in increm.of no great.than 200   GI disturbs., saliv. hypersecret., dysphag., swoll. tong., skin reacts.,   pts. treat.with other antipsychot., priapism poss.induc. with alpha-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page54.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page50.html">50</a>&nbsp;&nbsp;&nbsp;<a href="page51.html">51</a>&nbsp;&nbsp;&nbsp;<a href="page52.html">52</a>&nbsp;&nbsp;&nbsp;<a href="page53.html">53</a>&nbsp;&nbsp;&nbsp;<a href="page54.html">54</a>&nbsp;&nbsp;&nbsp;<a href="page55.html">55</a>&nbsp;&nbsp;&nbsp;<a href="page56.html">56</a>&nbsp;&nbsp;&nbsp;<a href="page57.html">57</a>&nbsp;&nbsp;&nbsp;<a href="page58.html">58</a>&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>
             </td>
             <td width="35%"><a href="page56.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page56.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
